USF-LVHN SELECT
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL.
Publication/Presentation Date
7-12-2022
Volume
6
Issue
13
First Page
3970
Last Page
3973
ISSN
2473-9537
Published In/Presented At
Perez, A., Johnson, G., Patel, K., Arciola, B., Wood, A., Bachmeier, C. A., Chavez, J. C., Shah, B. D., Khimani, F., Nishihori, T., Lazaryan, A., Davila, M. L., Mhaskar, R., Locke, F. L., Gaballa, S., & Jain, M. D. (2022). Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood advances, 6(13), 3970–3973. https://doi.org/10.1182/bloodadvances.2022007006
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
35816359
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article
COinS